Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
- DOI
- 10.1158/2767-9764.crc-25-0251
- Published
- 2025-09-01
- Container
- Cancer Research Communications
- Publisher
- American Association for Cancer Research (AACR)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1158/2767-9764.crc-25-0251,
title = {Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas},
author = {Niccolò G. Santin and Namrata Sethi and Stefania Bellone and Cem Demirkiran and Victoria M. Ettorre and Michelle Greenman and Blair McNamara and Natalia Buza and Tobias M.P. Hartwich and Luca Palmieri and Domenica Lorusso and Alessandro D. Santin},
year = {2025},
journal = {Cancer Research Communications},
doi = {10.1158/2767-9764.crc-25-0251},
url = {https://doi.org/10.1158/2767-9764.crc-25-0251}
}RIS
TY - JOUR TI - Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas AU - Niccolò G. Santin AU - Namrata Sethi AU - Stefania Bellone AU - Cem Demirkiran AU - Victoria M. Ettorre AU - Michelle Greenman AU - Blair McNamara AU - Natalia Buza AU - Tobias M.P. Hartwich AU - Luca Palmieri AU - Domenica Lorusso AU - Alessandro D. Santin PY - 2025 JO - Cancer Research Communications DO - 10.1158/2767-9764.crc-25-0251 UR - https://doi.org/10.1158/2767-9764.crc-25-0251 ER -
APA
Santin, N. G., Sethi, N., Bellone, S., Demirkiran, C., Ettorre, V. M., Greenman, M., McNamara, B., Buza, N., Hartwich, T. M., Palmieri, L., Lorusso, D., & Santin, A. D. (2025). Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-25-0251
Source records
- crossref · retrieved 2026-09-27T01:36:05.881Z